What dosage do you start tirzepatide on, and why does it matter?

Why 2.5 mg is the mandated starting point, not an option

The licensed schedule for tirzepatide (sold in the UK as Mounjaro) leaves no room for interpretation on this: 2.5 mg once weekly for the first four weeks. The reasoning is physiological. GIP and GLP-1 receptor agonists slow gastric emptying and dampen appetite signals, and introducing both effects at full strength from day one tends to produce pronounced nausea, vomiting or diarrhoea that leads people to stop treatment early. Starting low and moving slowly is how regulators (and the SURMOUNT clinical programme) landed on this schedule.

It is worth being direct about what this means in practice. During the first month, most people notice modest appetite changes but limited scale movement. That is expected. The 2.5 mg phase exists to settle your system, and it does that job well for most people. Trying to accelerate past it (by requesting a higher starting dose or switching pens mid-month) sits outside the licensed schedule and any reputable prescriber will decline.

If you want to understand the full ladder from 2.5 mg to 15 mg, the tirzepatide dosage overview on this site covers each step in detail.

The factors a prescriber weighs before deciding your titration pace

Starting dose is settled: 2.5 mg. But how quickly you move up is where individual assessment matters most. A prescriber reviewing your consultation (at nume, a GPhC-registered Independent Prescriber reads every submission the same day it arrives, not software) will consider several things before confirming a titration plan.

Your current health picture matters significantly. Someone with a history of gastrointestinal conditions may stay at a lower dose longer. Someone with well-controlled type 2 diabetes alongside their weight management goals has different monitoring needs than someone who is otherwise metabolically healthy. Concomitant medicines (particularly oral contraceptives, where absorption can be reduced during the first four weeks of tirzepatide and after each dose increase) are flagged and discussed at this stage.

Body weight at baseline does not on its own determine how fast you titrate. Tolerability does. A person at BMI 35 who sails through 2.5 mg and 5 mg with minimal side effects may reach higher doses faster than someone at BMI 42 who experiences notable nausea at each step. There is no prize for speed; the dose that produces results is the highest one you can tolerate comfortably, and that is different for everyone. The question of starting at 5 mg comes up regularly, the short answer is that prescribers follow the licensed schedule for good reason.

What 'highest tolerated dose' means in real terms

NICE's recommendation for tirzepatide (TA1026) uses the phrase "highest tolerated dose" deliberately. If you reach 10 mg or 12.5 mg and side effects at that level are persistent and affecting daily life, remaining on the dose below it is clinically appropriate. Pushing to 15 mg is not a requirement; it is the licensed ceiling, available where someone tolerates the path and where a prescriber judges it suitable.

The SURMOUNT-1 trial (which enrolled 2,539 adults with obesity and no diabetes) reported average weight reductions of around 20–21% at 15 mg over 72 weeks, a figure cited by NICE in TA1026. Lower maintenance doses produced meaningful results too, which is the clinical basis for staying at a tolerated dose rather than pushing through difficult side effects in pursuit of the maximum.

For reference on what the intermediate steps look like, the 5 mg dosage page and the 10 mg dosage page cover those phases specifically. A visual summary of the full schedule is on the tirzepatide dosage chart.

Practically speaking: what happens after you start

Once your prescription is written and your first pen arrives (dispatched the same working day for orders in by midday, delivered free next day by DPD in plain packaging) you begin your first four weeks at 2.5 mg. One injection per week, same day each week, rotating between your abdomen, thigh and upper arm. After four weeks, your prescriber reviews your progress and tolerance before any dose increase. That review happens before every repeat order at nume; no automatic escalation, no assumption that more is always better.

On cost: dose affects the price of each pen, and the context behind Mounjaro's UK pricing is worth understanding before you start. Current pricing is shown on the treatment page.

Side effects at any dose should be reported to your prescriber. If you experience severe, persistent stomach pain (particularly if it spreads to your back) seek medical attention promptly; acute pancreatitis, while uncommon, is a known risk with GLP-1 medicines. The NHS tirzepatide page and the medicine's Patient Information Leaflet are the authoritative references for the full side-effect picture; never adjust your own dose or timing without clinical input.